cancer vaccine

July 9, 2020July 9, 2020

Vaccine Shows Promise in Advanced Prostate Cancer, Proof-of-Concept Study Shows

News

YourVaccx, a new type of cancer vaccine developed by ImmunSYS, is safe and shows promising effectiveness in patients with metastatic prostate cancer and other difficult-to-treat advanced solid tumors, a proof-of-concept ... Read more

April 17, 2020April 17, 2020

Cancer Vaccine Plus Opdivo Showing Promise in Advanced Prostate Cancer Trial

News

A combination of Vaccitech’s experimental vaccine VTP-800 and Opdivo (nivolumab) appears to be a safe and potentially effective treatment for men with metastatic castration resistant prostate cancer (mCRPC), according to early data from ... Read more

April 11, 2019

ADXS-PSA/Keytruda Combo Prolongs Survival in mCRPC, Early Trial Results Suggest

News

Adding ADXS-PSA, an investigational cancer vaccine, to Keytruda (pembrolizumab) is showing positive signs of safety and efficacy in patients with metastatic, castration-resistant prostate cancer (mCRPC), and appears to prolong survival ... Read more

October 11, 2018

OncBioMune Readies for Enrollment in Phase 2 Trial of ProscaVax Vaccine

News

OncBioMune Pharmaceuticals soon will initiate a Phase 2 trial evaluating the effectiveness and safety of its lead immunotherapy, ProscaVax, for men with early-stage prostate cancer. In a recent update, the company announced that ... Read more

February 5, 2018

Panacea Completes Patient Enrollment in Phase 1 Trial of Prostate Cancer Vaccine

News

Panacea Pharmaceuticals has completed patient enrollment in a Phase 1 clinical trial testing its PAN-301-1 vaccine as a treatment for prostate cancer that has failed to respond to other therapies. The multi-center trial (NCT03120832) ... Read more

January 17, 2018

ProscaVax Reduced Tumor Growth in 70% of Prostate Cancer Patients, Early-stage Study Shows

News

OncBioMune‘s investigational cancer vaccine ProscaVax reduced tumor growth in 70% of prostate cancer patients included in a Phase 1a study. The immunotherapy candidate consists of a combination of the PSA protein ... Read more

June 14, 2017June 14, 2017

Indoximod and Provenge Combo Lengthens Time for Prostate Cancer to Progress, Trial Shows

News

A combination of NewLink Genetics‘ immunotherapy indoximod and the cancer vaccine Provenge more than doubled the time it took for an advanced cancer patient’s disease to progress, compared with Provenge alone, ... Read more

March 29, 2017March 29, 2017

Study of MVI-118 Prostate Cancer Vaccine Expands, Adding Site in Seattle

News

A Phase 1 study evaluating the MVI-118 cancer vaccine in patients with metastatic prostate cancer is expanding to a third clinical site, the University of Washington in Seattle. The trial ... Read more

January 2, 2015January 2, 2015

Trial Shows Safety of Vaccine Therapy for Prostate Cancer Patients

News

An international team of researchers has shown that a specific vaccine therapy that activates a patient’s immune response can be safely administered to prostate cancer patients. The Phase II clinical ... Read more